Zentalis Pharmaceuticals
ZNTL
61 hedge funds and large institutions have $1.28B invested in Zentalis Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 61 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
74.86% more ownership
Funds ownership: 0% → 74.86% (+75%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$170M |
| 2 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$147M |
| 3 |
TCM
Tybourne Capital Management
Hong Kong
|
+$102M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$88.6M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$63.7M |
Top Sellers
ZNTL Hedge Fund Activity: Q2 2020 in Review
61 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q2 2020, worth a combined $1.28B.
Buyers outnumbered sellers: 61 funds opened new ZNTL positions and 0 closed out — a net gain of 61 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $170M.
- 61 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $1.28B of Zentalis Pharmaceuticals stock for Q2 2020.
- 61 funds opened new Zentalis Pharmaceuticals positions in Q2 2020 and 0 closed out, a net change of +61 holders.
- The largest Zentalis Pharmaceuticals buyer in Q2 2020 was Viking Global Investors, an estimated $170M added.
Based on aggregated 13F filings for Q2 2020.